ATE534391T1 - 3,11b-cis-dihydrotetrabenazin zur behandlung von psychosen - Google Patents

3,11b-cis-dihydrotetrabenazin zur behandlung von psychosen

Info

Publication number
ATE534391T1
ATE534391T1 AT08170385T AT08170385T ATE534391T1 AT E534391 T1 ATE534391 T1 AT E534391T1 AT 08170385 T AT08170385 T AT 08170385T AT 08170385 T AT08170385 T AT 08170385T AT E534391 T1 ATE534391 T1 AT E534391T1
Authority
AT
Austria
Prior art keywords
dihydrotetrabenazine
psychoses
cis
treatment
schizophrenia
Prior art date
Application number
AT08170385T
Other languages
English (en)
Inventor
Andrew John Duffield
Jean Elisabeth Yarrow
Original Assignee
Biovail Lab Internat Barbados Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0516167.4A external-priority patent/GB0516167D0/en
Priority claimed from GB0516790A external-priority patent/GB0516790D0/en
Application filed by Biovail Lab Internat Barbados Srl filed Critical Biovail Lab Internat Barbados Srl
Application granted granted Critical
Publication of ATE534391T1 publication Critical patent/ATE534391T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT08170385T 2005-08-06 2006-08-04 3,11b-cis-dihydrotetrabenazin zur behandlung von psychosen ATE534391T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0516167.4A GB0516167D0 (en) 2005-08-06 2005-08-06 Pharmaceutical compounds
GB0516790A GB0516790D0 (en) 2005-08-16 2005-08-16 Pharmaceutical compounds

Publications (1)

Publication Number Publication Date
ATE534391T1 true ATE534391T1 (de) 2011-12-15

Family

ID=37400949

Family Applications (2)

Application Number Title Priority Date Filing Date
AT06765238T ATE415968T1 (de) 2005-08-06 2006-08-04 3,11b-cis-dihydrotetrabanezin zur behandlung von schizophrenie und anderen psychosen
AT08170385T ATE534391T1 (de) 2005-08-06 2006-08-04 3,11b-cis-dihydrotetrabenazin zur behandlung von psychosen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT06765238T ATE415968T1 (de) 2005-08-06 2006-08-04 3,11b-cis-dihydrotetrabanezin zur behandlung von schizophrenie und anderen psychosen

Country Status (21)

Country Link
US (1) US20110257220A1 (de)
EP (2) EP1855677B1 (de)
JP (1) JP2009504622A (de)
KR (1) KR20080033500A (de)
AT (2) ATE415968T1 (de)
AU (1) AU2006277753B2 (de)
CA (1) CA2620960A1 (de)
CY (1) CY1108843T1 (de)
DE (1) DE602006004009D1 (de)
DK (1) DK1855677T3 (de)
ES (1) ES2318771T3 (de)
HK (1) HK1111083A1 (de)
HR (1) HRP20090074T3 (de)
MX (1) MX2008001549A (de)
NZ (1) NZ566011A (de)
PL (1) PL1855677T3 (de)
PT (1) PT1855677E (de)
RS (1) RS50807B (de)
RU (1) RU2407743C2 (de)
SI (1) SI1855677T1 (de)
WO (1) WO2007017654A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8039627B2 (en) 2006-11-08 2011-10-18 Neurocrine Biosciences, Inc. Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-A]isoquinolin-2-ol compounds and methods relating thereto
US7897768B2 (en) 2007-06-08 2011-03-01 General Electric Company Method for making tetrabenazine compounds
US8053578B2 (en) 2007-11-29 2011-11-08 General Electric Company Alpha-fluoroalkyl dihydrotetrabenazine imaging agents and probes
GB0810857D0 (en) * 2008-06-13 2008-07-23 Cambridge Lab Ireland Ltd Pharmaceutical compounds
GB2463283A (en) * 2008-09-08 2010-03-10 Cambridge Lab 3,11b-cis-dihydrotetrabenazine for use in treating asthma
GB2463451A (en) * 2008-09-08 2010-03-17 Cambridge Lab 3, 11b cis-dihydrotetrabenazine compounds for use in the treatment of dementia
EP2576552A4 (de) 2010-06-01 2013-11-13 Aupex Pharmaceutical Inc Benzochinolonhemmer von vmat2
JP6010108B2 (ja) 2011-04-01 2016-10-19 スリーエム イノベイティブ プロパティズ カンパニー トリアジン系紫外線吸収剤を含むフィルム
CA2936823A1 (en) 2014-01-27 2015-07-30 Auspex Pharmaceuticals, Inc. Benzoquinoline inhibitors of vesicular monoamine transporter 2
US9782398B2 (en) * 2014-02-07 2017-10-10 Neurocrine Biosciences, Inc. Pharmaceutical compositions comprising an antipsychotic drug and a VMAT2 inhibitor and uses thereof
SG11201803408PA (en) 2015-10-30 2018-05-30 Neurocrine Biosciences Inc Valbenazine salts and polymorphs thereof
EP3394057B1 (de) 2015-12-23 2022-03-30 Neurocrine Biosciences, Inc. Synthetisches verfahren zur herstellung von (s)-(2r, 3r, 11br)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1h-pyrido[2,1,-a]llsochinolin-2-yl-2-amino-3-methylbutanoat-di(4-methylbenzenesulfonat)
EP3548027A1 (de) * 2016-12-02 2019-10-09 Neurocrine Biosciences, Inc. Verwendung von valbenazin zur behandlung von schizophrenie oder schizoaffektiver störung
CN110709071A (zh) 2017-01-27 2020-01-17 纽罗克里生物科学有限公司 用于施用某些vmat2抑制剂的方法
GB201705303D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705306D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705304D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705302D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
CN111372567B (zh) 2017-09-21 2024-03-15 纽罗克里生物科学有限公司 高剂量的缬苯那嗪制剂和与其相关的组合物、方法和试剂盒
AU2017435893B2 (en) 2017-10-10 2023-06-29 Neurocrine Biosciences, Inc Methods for the administration of certain VMAT2 inhibitors
US10993941B2 (en) 2017-10-10 2021-05-04 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors
SG11202100303QA (en) 2018-08-15 2021-02-25 Neurocrine Biosciences Inc Methods for the administration of certain vmat2 inhibitors
US10940141B1 (en) 2019-08-23 2021-03-09 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2843591A (en) 1958-07-15 Method for preparing same
US2830993A (en) 1958-04-15 Quinolizine derivatives
US6087376A (en) * 1997-02-05 2000-07-11 University Of Kentucky Research Foundation Use of lobeline compounds in the treatment of central nervous system diseases and pathologies
GB2410947B (en) * 2004-02-11 2008-09-17 Cambridge Lab Ltd Pharmaceutical compounds

Also Published As

Publication number Publication date
PT1855677E (pt) 2009-01-13
US20110257220A1 (en) 2011-10-20
EP1855677B1 (de) 2008-12-03
DE602006004009D1 (de) 2009-01-15
EP2050451B1 (de) 2011-11-23
EP2050451A1 (de) 2009-04-22
ATE415968T1 (de) 2008-12-15
HRP20090074T3 (en) 2009-04-30
AU2006277753A1 (en) 2007-02-15
RU2407743C2 (ru) 2010-12-27
KR20080033500A (ko) 2008-04-16
RU2008108623A (ru) 2009-09-20
RS50807B (sr) 2010-08-31
WO2007017654A1 (en) 2007-02-15
AU2006277753B2 (en) 2011-11-10
EP1855677A1 (de) 2007-11-21
NZ566011A (en) 2011-01-28
CA2620960A1 (en) 2007-02-15
HK1111083A1 (en) 2008-08-01
JP2009504622A (ja) 2009-02-05
SI1855677T1 (sl) 2009-04-30
PL1855677T3 (pl) 2009-07-31
ES2318771T3 (es) 2009-05-01
DK1855677T3 (da) 2009-02-09
CY1108843T1 (el) 2014-07-02
MX2008001549A (es) 2008-04-04

Similar Documents

Publication Publication Date Title
ATE534391T1 (de) 3,11b-cis-dihydrotetrabenazin zur behandlung von psychosen
DE602004020072D1 (de) 1,2,3,4-tetrasubstituiertes indol zur behandlung von atemwegserkrankungen
ATE412414T1 (de) 3,11b-cis-dihydrotetrabenazin zur behandlung von proliferativen krankheiten oder entzündungen
ATE410430T1 (de) 2,3-dihydro-6-nitroimidazoä2,1- büoxazolverbindungen zur behandlung von tuberkulose
DE602005019247D1 (de) Verwendung von cyclodextrin zur behandlung und vorbeugung von entzündlichen bronchialerkrankungen
EA200601837A1 (ru) Бензоксазины для лечения заболеваний дыхательных путей
TW200612910A (en) Medicaments comprising carbonyl compounds, and the use thereof
ATE550338T1 (de) Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
HK1092467A1 (en) N-alkyl-hydroxamic acid-isoindolyl compounds and their pharmaceutical uses n-
ATE408601T1 (de) Fredericamycin-derivate
RS51069B (sr) Upotreba oksikodona za tretiranje visceralnog bola
DK1594833T3 (da) 1-phenylalkancarboxylsyrederivater til behandling af neurodegenerative sygdomme
DE602006020871D1 (de) Lineare harnstoffmimetika-antagonisten des p2y1-rezeptors zur behandlung von thromboseleiden
DE602006010738D1 (de) Pyrroloä2,3-cüpyridinderivate
DE602007005697D1 (de) Verwendung von carrageenan zur behandlung von rhinovirus-infektionen
ATE357438T1 (de) 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems
DE602006003094D1 (de) 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydrochinolin-derivate zur behandlung von unfruchtbarkeit
DE602004003952D1 (de) Substituierte tetrahydrobenzothienopyrimidinamine verbindungen geeignet zur behandlung von hyper-proliferative disorders
BR0316723A (pt) Derivados de anilinopirazol úteis para o tratamento de diabetes
DE602006002608D1 (de) 4-phenyl-5-oxo-l,4,5,6,7,8-hexahydrochinolin-derivate als arzneimittel zur behandlung von unfruchtbarkeit
CY1110027T1 (el) Συνδυασμος ενωσεων πυριμιδυλαμινοβενζαμιδης και ιματινιβης για τη θεραπεια ή την προληψη των νεοπλασματικων ασθενειων
ATE485820T1 (de) Verwendung von n-(dibenz (b,f)oxepin-10-ylmethyl)-n-methyl-n-prop-2-inyl min (omigapil) zur prophylaxe und/oder behandlung von muskeldystrophie
DE602004020337D1 (de) Anticholinergika enthaltende Arzneimittel zur Behandlung von Krankheiten der ableitenden Harnwege
ATE473737T1 (de) Verwendung von 2,3-dehydronaringenin-derivaten zur behandlung von entzündungsprozessen und diese derivate enthaltende pharmazeutische zusammensetzung